The treatment of chronic pyelonephritis with carindacillin.

Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol (1992) 4.79

DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res (1999) 4.67

Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res (1992) 2.55

Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res (1994) 2.34

Characterization of human c-fes/fps reveals a new transcription unit (fur) in the immediately upstream region of the proto-oncogene. Mol Biol Rep (1986) 2.16

Automated prostate volume determination with ultrasonographic imaging. J Urol (1995) 2.13

Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res (1993) 2.09

Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res (1992) 1.98

Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol (1996) 1.64

fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas. J Clin Invest (1987) 1.63

4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol (2000) 1.61

A practical clinical method for contour determination in ultrasonographic prostate images. Ultrasound Med Biol (1994) 1.60

Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol (1998) 1.59

Selective detrusor activation by electrical sacral nerve root stimulation in spinal cord injury. J Urol (1997) 1.58

Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer (1995) 1.58

TNM classification of genitourinary tumours 1987--position of the EORTC Genitourinary Group. Br J Urol (1988) 1.55

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol (1997) 1.46

Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res (1996) 1.41

Quality-of-life assessment in patients after laser prostatectomy. Br J Urol (1997) 1.41

Urinary tract infections following laser prostatectomy: is there a need for antibiotic prophylaxis? Br J Urol (1996) 1.38

Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients. Dutch South Eastern Bladder Cancer Study Group. Eur J Cancer (1994) 1.38

Comparison of different computer models of the neural control system of the lower urinary tract. Neurourol Urodyn (2000) 1.37

Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. Prostate (1988) 1.35

Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol (1997) 1.35

The effects of treatment of urinary incontinence in general practice. Fam Pract (1992) 1.32

Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. Cancer Res (1993) 1.29

Identification of intermediate cell types by keratin expression in the developing human prostate. Prostate (1998) 1.27

Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy (1985) 1.23

Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res (1992) 1.23

Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis. Eur Urol (1999) 1.22

Controlled trial of pelvic floor exercises in the treatment of urinary stress incontinence in general practice. Br J Gen Pract (1991) 1.22

The correlation between bladder outlet obstruction and lower urinary tract symptoms as measured by the international prostate symptom score. J Urol (1996) 1.19

Molecular analysis of multifocal prostate cancer lesions. J Pathol (1999) 1.19

Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res (1999) 1.19

Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol (1993) 1.18

Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis. Cancer Res (1991) 1.18

Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer (1997) 1.17

Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res (1991) 1.17

Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother (1991) 1.16

Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother (1992) 1.15

High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. Prostate (1999) 1.13

Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol (1993) 1.12

Value of the patient's case history in diagnosing urinary incontinence in general practice. Br J Urol (1991) 1.12

Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J Urol (1995) 1.11

Treatment of mid- and lower ureteric calculi: extracorporeal shock-wave lithotripsy vs laser ureteroscopy. A comparison of costs, morbidity and effectiveness. Br J Urol (1998) 1.11

Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction. J Urol (2001) 1.08

Results of the treatment of neurogenic bladder dysfunction in spinal cord injury by sacral posterior root rhizotomy and anterior sacral root stimulation. J Urol (1996) 1.08

Influence of high-intensity focused ultrasound on the development of metastases. Eur Urol (1997) 1.07

Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology (1996) 1.07

A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization. Br J Cancer (1996) 1.07

Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group. Cancer Chemother Pharmacol (1992) 1.05

Grading in superficial bladder cancer. (1). Morphological criteria. Br J Urol (1988) 1.04

Rapid microwave-stimulated fixation of entire prostatectomy specimens. Biomed-II MPC Study Group. J Pathol (1997) 1.04

Reliability of the International Prostate Symptom Score in the assessment of patients with lower urinary tract symptoms and/or benign prostatic hyperplasia. J Urol (1996) 1.02

Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview. Urol Int (1990) 1.02

Personality variables involved in chronic prostatitis. Urology (1993) 1.01

Sexual function following high energy microwave thermotherapy: results of a randomized controlled study comparing transurethral microwave thermotherapy to transurethral prostatic resection. J Urol (1999) 1.01

The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia. J Urol (1996) 1.01

Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology (1997) 1.01

Spontaneous renal decapsulation with excessive fluid leakage after transplantation. N Engl J Med (1979) 0.99

Variability of pressure-flow analysis parameters in repeated cystometry in patients with benign prostatic hyperplasia. J Urol (1995) 0.99

Epidemiology of prostate cancer. Eur Urol (1996) 0.99

Establishment and characterization of five new human renal tumor xenografts. Am J Pathol (1992) 0.99

Variability of clinical and pressure-flow study variables after 6 months of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargement. J Urol (1996) 0.99

Extracorporeal shock wave lithotripsy for large renal calculi: the role of ureteral stents. A randomized trial. J Urol (1991) 0.99

Improved reliability of uroflowmetry investigations: results of a portable home-based uroflowmetry study. Br J Urol (1996) 0.97

Decreased expression of alpha-catenin is associated with poor prognosis of patients with localized renal cell carcinoma. Int J Cancer (1997) 0.96

A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol (1995) 0.95

Comparison of biothesiometry and neuro-urophysiological investigations for the clinical evaluation of patients with erectile dysfunction. J Urol (1995) 0.95

Squamous and transitional elements in rat bladder carcinomas induced by N-butyl-N-4-hydroxybutyl-nitrosamine (BBN). A study of cytokeratin expression. Am J Pathol (1985) 0.95

The correlation between urodynamic and cystoscopic findings in elderly men with voiding complaints. J Urol (1996) 0.94

Expression of cadherin-6 as a novel diagnostic tool to predict prognosis of patients with E-cadherin-absent renal cell carcinoma. Clin Cancer Res (1998) 0.94

Can biological markers replace cystoscopy? An update. Curr Opin Urol (2001) 0.93

Assessment of penile blood flow by duplex ultrasonography in 44 men with normal erectile potency in different phases of erection. J Urol (1992) 0.93

In-use evaluation of the Omnicon automated tumor colony counter. Cytometry (1983) 0.93

Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Members of the Dutch South-East Co-Operative Urological Group. Br J Urol (1994) 0.93

The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. Br J Cancer (1993) 0.92

Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology (1993) 0.91

Transrectal high-intensity focused ultrasound using the Ablatherm device in the treatment of localized prostate carcinoma. Urology (1999) 0.91

Internal image anti-idiotype antibodies related to renal-cell carcinoma-associated antigen G250. Int J Cancer (1994) 0.91

Cytotoxic effects of high energy shock waves in different in vitro models: influence of the experimental set-up. J Urol (1991) 0.91

Microvessel density: correlation between contrast ultrasonography and histology of prostate cancer. Eur Urol (2001) 0.91

Urodynamic results of laser treatment in patients with benign prostatic hyperplasia. Can outlet obstruction be relieved? J Urol (1995) 0.90

Psychological aspects of female urinary incontinence in general practice. Br J Urol (1992) 0.90

Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas. J Urol (1994) 0.89

Transrectal ultrasound of the prostate: innovations and future applications. J Urol (1998) 0.89

p53 mutations have no additional prognostic value over stage in bladder cancer. Br J Cancer (1994) 0.89

The use of local anesthesia in second generation extracorporeal shock wave lithotripsy: eutectic mixture of local anesthetics. J Urol (1991) 0.88

Predictors of success with neuromodulation in lower urinary tract dysfunction: results of trial stimulation in 100 patients. J Urol (1994) 0.88

Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects. Lab Invest (1995) 0.88

Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer. Eur J Cancer (1994) 0.88

Formula-derived prostate volume determination. Eur Urol (1996) 0.87

Seminal vesicle cyst with ipsilateral renal agenesis. Urol Int (1993) 0.87

Bladder carcinoma in patients less than 40 years of age. Urol Int (1989) 0.87

Fibroepithelial polyp of ureter. Urology (1980) 0.87

Is detrusor instability in elderly males related to the grade of obstruction? Neurourol Urodyn (1995) 0.87

Reproducibility of prostate volume measurements from transrectal ultrasonography by an automated and a manual technique. Br J Urol (1996) 0.87

Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities. Eur Urol (1992) 0.87

Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette-Guerin. In Vivo (1992) 0.86